Immune-guided vs universal medicine to prevent CMV after kidney transplant
Part of Immune system & allergy, Infections, Kidney & urinary clinical trials.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a kidney transplant 1 to 12 days ago.
- Your CMV blood test before transplant shows CMV “IgG positive” (a specific lab threshold).
- Before your transplant, you received basiliximab to prevent organ rejection (not antithymocyte/anti-thymoglobulin medicines).
- Your current blood counts are safe: neutrophils are at least 500/mm³, platelets at least 25,000/mm³, and hemoglobin at least 8 g/L.
- You must not already have active CMV infection (your CMV DNA test in blood must be below the study’s cutoff).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study looks at how CMV (a common virus) affects the immune system in people who get a kidney transplant or have CMV after transplant. It may help doctors understand and manage CMV better.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Hear when a new Kidney Transplant Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.